LeeSRosenMD

Hematology • Santa Monica, CA

Myeloproliferative Disorder Hematology-Oncology

Professor, Medicine, University of California Los Angeles David Geffen SOM

Join to view full profile

Dr. Rosen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Rosen's full profile

Already have an account?

Office
2020 Santa Monica Blvd., Suite 600
Santa Monica, CA 90404
Phone+1 310-829-5471

Fax+1 310-829-5471
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1990 - 1993
Baylor College of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 1991 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2011
Super Doctor SuperDoctors.com

Clinical Trials

Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer Start of enrollment: 2001 Apr 01
Unknown status
Phase 1
Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2000 Dec 01
Unknown status
Phase 3
Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2001 Sep 01
Unknown status
Phase 1
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors Start of enrollment: 2008 Jan 01
Terminated
Phase 1
Futibatinib in Patients With Specific FGFR Aberrations Start of enrollment: 2020 Aug 24
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.
Danny N Khalil, Isabel Prieto González-Albo, Lee Rosen, Tom Lillie, Andrea Stacey, Lola Parfitt, Gerald A Soff> ;Investigational New Drugs. 2023 Mar 10
7 citations
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
Alexander Drilon, Daniel S W Tan, Ulrik N Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D Patel, Lee Rosen, Benjamin Solomon, Ricarda Norenberg, Laura Dima, Nicoletta Breg...> ;JCO Precision Oncology. 2022 Jan 1
Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort.
Sarah F. DAmbruoso, John A. Glaspy, Sara A. Hurvitz, Neil S. Wenger, Christopher Pietras, Kauser Ahmed, Alexandra Drakaki, Jonathan W. Goldman, Sidharth Anand, Wendy S...> ;JCO Oncology Practice. 2021 Nov 8
14 citations
Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels
Isabel Kurth, Norihiro Yamaguchi, Celia Andreu-Agullo, Helen S. Tian, Subhasree Sridhar, Shugaku Takeda, Foster C. Gonsalves, Jia Min Loo, Afsar Barlas, Katia Manova-T...> ;Science Advances. 2021 Oct 8
8 citations
A Randomized Phase 2 Study Of Nivolumab Monotherapy Or Nivolumab Combined with Ipilimumab In Patients with Advanced Gastrointestinal Stromal Tumors
Arun S. Singh, J. Randolph Hecht, Lee S. Rosen, Zev A. Wainberg, Xiaoyan Wang, Michael Douek, Anahis Hagopian, Rachel Andes, Lauren Sauer, Sandra Brackert, Warren Chow...> ;Clinical Cancer Research. 2021 Aug 18
4 citations
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal im...
Muhammad Wasif Saif, Carlos Becerra, Marwan Fakih, Weijing Sun, Lazar Popovic, Smitha S. Krishnamurthi, Thomas J. George, Michelle A. Rudek, Dale R. Shepard, Jiri Skop...> ;Cancer Chemotherapy and Pharmacology. 2021 Jun 7
6 citations
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data fr...
Victor Moreno, Pilar Garrido, Kyriakos P. Papadopoulos, Maria Jose De Miguel Luken, Marta Gil-Martin, Raid Aljumaily, Lee S. Rosen, P. Rietschel, Kosalai Kal Mohan, Su...> ;Lung Cancer. 2021 May 1
31 citations
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low Dose Cyclophosphamide in Patients with Advanced Malignancies.
Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Albert C. Lockhart, Kathleen N. Moore, Gerald Steven Falchook, Silvia C. Formenti, Aung Naing, Richard D. Carvajal, Le...> ;Clinical Cancer Research. 2020 Mar 1
26 citations
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors
Lee S. Rosen, Robert Wesolowski, Raffaele Baffa, Kai-Hsin Liao, Steven Y. Hua, Brenda Gibson, Steven Pirie-Shepherd, Anthony W. Tolcher> ;Investigational New Drugs. 2020 Feb 1
5 citations
Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Muhammad Wasif Saif, Lee S. Rosen, Michelle A. Rudek, Weijing Sun, Dale R. Shepard, Carlos Becerra, Fumiaki Yamashita, Paul Bebeau, Robert Winkler> ;British Journal of Clinical Pharmacology. 2019 Jun 1
7 citations
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer
Jonathan W. Goldman, Lee S. Rosen, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Peipei Shi, Celine Pitou, Robert Bell, Palaniappan Kulanthaivel, Xu...> ;Investigational New Drugs. 2018 Aug 1
11 citations
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
Colin D. Weekes, Lee S. Rosen, Anna Capasso, Kit Man Wong, Weilan Ye, Maria Anderson, Bruce McCall, Jill Fredrickson, Eric Wakshull, Steve Eppler, Quyen Shon-Nguyen, R...> ;Cancer Chemotherapy and Pharmacology. 2018 Jun 15
13 citations
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Jeffrey R Infante, Ronald L Korn, Lee S Rosen, Patricia LoRusso, Samuel S Dychter, Joy Zhu, Daniel C Maneval, Ping Jiang, H Michael Shepard, Gregory Frost, Daniel D Vo...> ;British journal of cancer. 2018 Jan 1
9 citations
Erratum: Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours (British journal of cancer (2018) 118 2 (153-161))
Jeffrey R. Infante, Ronald L. Korn, Lee S. Rosen, Patricia LoRusso, Samuel S. Dychter, Joy Zhu, Daniel C. Maneval, Ping Jiang, H. Michael Shepard, Gregory I. Frost, Da...> ;British Journal of Cancer. 2018 Jan 1
73 citations
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.
Lee S. Rosen, Ira Jacobs, Ronald L. Burkes> ;Targeted Oncology. 2017 Oct 1
42 citations
A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer
Lee S. Rosen, Jonathan W. Goldman, Alain Algazi, P. Kellie Turner, Brian A. Moser, Tianle Hu, Xuejing Aimee Wang, Jay Tuttle, Volker Wacheck, James E. Wooldridge, Mich...> ;Clinical Cancer Research. 2017 Apr 15
10 citations
Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population
Jill Fredrickson, Natalie J. Serkova, Shelby K. Wyatt, Richard A.D. Carano, Andrea Pirzkall, Ina Rhee, Lee S. Rosen, Alberto Bessudo, Colin D. Weekes, Alex de Crespigny> ;Magnetic Resonance in Medicine. 2017 Feb 1
24 citations
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
James M. Cleary, Lee S. Rosen, Kenichiro Yoshida, Drew W. Rasco, Geoffrey I. Shapiro, Weijing Sun> ;Investigational New Drugs. 2017 Jan 23
140 citations
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick, Raoul Tibes, Lee S. Rosen, Albiruni Ryan Abdul Razak, Raymond Lam, Tim Demuth, Shelonitda Rose, Mark A Lee, Tom...> ;Journal of Clinical Oncology. 2016 Oct 31
46 citations
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
Lee S. Rosen, Patricia LoRusso, Wen Wee Ma, Jonathan W. Goldman, Amy Weise, A. Dimitrios Colevas, Alex A. Adjei, Salim Yazji, Angela Shen, Stuart Johnston, Hsin Ju Hsi...> ;Investigational New Drugs. 2016 Jul 16
409 citations
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew W. Rasco, John H...> ;Cancer Discovery. 2016 May 23
9 citations
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
Gerald Steven Falchook, Xiaofei Zhou, Karthik Venkatakrishnan, Razelle Kurzrock, Devalingam Mahalingam, Jonathan W. Goldman, JungAh A. Jung, Claudio Dansky Ullmann, Ca...> ;Drugs in R & D. 2016 Mar 1
Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Johanna C. Bendell, Lee S. Rosen, Robert J. Mayer, Jonathan W. Goldman, Jeffrey R. Infante, Fabio Benedetti, Donghu Lin, Hirokazu Mizuguchi, C. Zergebel, Manish R. Patel> ;Cancer Chemotherapy and Pharmacology. 2016 Feb 1
24 citations
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Anthony W. Tolcher, Patricia LoRusso, Jennifer Arzt, Todd A. Busman, Guinan Lian, Niki S. Rudersdorf, Carol Ann Vanderwal, Jeffrey F. Waring, Jianning Yang, Kyle D. Ho...> ;Cancer Chemotherapy and Pharmacology. 2015 Oct 1
40 citations
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
Anthony W. Tolcher, Patricia LoRusso, Jennifer Arzt, Todd A. Busman, Guinan Lian, Niki S. Rudersdorf, Carol Ann Vanderwal, Whitney P. Kirschbrown, Kyle D. Holen, Lee S...> ;Cancer Chemotherapy and Pharmacology. 2015 Sep 29
Join now to see all